Asset Details
Do you wish to reserve the book?
ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study
Do you wish to request the book?
ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study
2024
Overview
Xylazine exacerbates the respiratory depression induced by fentanyl. Because xylazine is a non-opioid, it is resistant to reversal by opioid receptor antagonists such as naloxone (e.g., Narcan
), thereby complicating attempts at treatment of fentanyl overdose. Antagonists of large-conductance potassium BK (big potassium) channels (BK
) in the carotid bodies reverse drug-induced hypoxia (decreased pO
) and hypercapnia (increased pCO
). In animals and human volunteers, the selective BK antagonist ENA-001 reverses the respiratory depression induced by opioids and non-opioids, i.e., it is an \"agnostic\" respiratory reversal agent. Given the seriousness of xylazine plus fentanyl combination (XFC) overdose, the present pilot study in rats was designed to evaluate the potential of a single intravenous bolus of ENA-001 to mitigate the acute respiratory depression induced by a prior intravenous bolus infusion of an XFC. XFC-induced respiratory depression was manifested as a decrease in pO
and an increase in pCO
. ENA-001, but not the vehicle, rapidly reversed these XFC-induced changes. Based on the results of this pilot study, the \"agnostic\" nature of ENA-001 respiratory stimulation appears to extend to XFC-induced overdose. Given the urgent clinical need, additional study seems warranted.
Publisher
Cureus
Subject
